These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10096425)

  • 1. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies.
    Stein GM; Pfüller U; Berg PA
    Cancer Lett; 1999 Jan; 135(2):165-70. PubMed ID: 10096425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts.
    Stein GM; Stettin A; Schultze J; Berg PA
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S57-9. PubMed ID: 9179370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
    Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
    Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of isolated mistletoe lectin chains in plant extracts.
    Tonevitsky AG; Marx U; Agapov I; Moisenovich M
    Arzneimittelforschung; 2002; 52(1):67-71. PubMed ID: 11838276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro.
    Stettin A; Schultze JL; Stechemesser E; Berg PA
    Klin Wochenschr; 1990 Sep; 68(18):896-900. PubMed ID: 2124308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
    Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
    Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ingredients of mistletoe (Viscum album L.) as potential drugs].
    Franz H
    Pharmazie; 1985 Feb; 40(2):97-104. PubMed ID: 3889937
    [No Abstract]   [Full Text] [Related]  

  • 8. Mistletoe lectins: telomerase inhibitors in alternative cancer therapy.
    Li SS
    Drug Discov Today; 2002 Sep; 7(17):896-7. PubMed ID: 12546929
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of major antigenic determinants in Mistletoe lectin I].
    Maliuchenko NV; Moĭsenovich MM; Egorova SG; Gusarova VIu; Agapov II; Balashova TA; Tonevitskiĭ AG
    Biofizika; 1999; 44(6):1017-21. PubMed ID: 10707276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The mistletoe myth--claims, reality and provable perspectives].
    Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
    Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mistletoe in immunology and the clinic (short review).
    Stein GM; Schietzel M; Büssing A
    Anticancer Res; 1998; 18(5A):3247-9. PubMed ID: 9858890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins.
    Ribéreau-Gayon G; Jung ML; Frantz M; Anton R
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S3-8. PubMed ID: 9179359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood and tissue eosinophilia, mistletoe lectin antibodies and quality of life in a breast cancer patient undergoing intratumoral and subcutaneous mistletoe therapy].
    Kröz M; Schad F; Matthes B; Pickartz H; Girke M
    Forsch Komplementarmed Klass Naturheilkd; 2002 Jun; 9(3):160-7. PubMed ID: 12119512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.
    Mengs U; Göthel D; Leng-Peschlow E
    Anticancer Res; 2002; 22(3):1399-407. PubMed ID: 12168816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of immunoactive mistletoe lectin-I.
    Beuth J
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating unconventional therapies.
    Hajto T; Saller R
    CMAJ; 1998 Oct; 159(7):759; author reply 759, 761. PubMed ID: 9805018
    [No Abstract]   [Full Text] [Related]  

  • 17. Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain.
    Eck J; Langer M; Möckel B; Baur A; Rothe M; Zinke H; Lentzen H
    Eur J Biochem; 1999 Sep; 264(3):775-84. PubMed ID: 10491123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
    Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties.
    Holtskog R; Sandvig K; Olsnes S
    Oncology; 1988; 45(3):172-9. PubMed ID: 3368193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new gene encoding the ribosome-inactivating protein from mistletoe extracts.
    Tonevitsky AG; Agapov II; Pevzner IB; Maluchenko NV; Moisenovich MM; Palmer RA; Yurkova M; Pfüller K; Pfüller U
    Arzneimittelforschung; 2004; 54(4):242-9. PubMed ID: 15146937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.